[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622055":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":34,"centralContacts":39,"locations":45,"responsibleParty":196,"collaborators":34,"id":198,"slug":34,"hasResults":199,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":199,"sex":205,"minAge":206,"maxAge":34,"enrollmentInfo":207,"targetDuration":34,"studyType":210,"phases":211,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":48,"whyStopped":34,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":233},{"fullName":5,"class":6},"Skyhawk Therapeutics, Inc.","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Active Comparator (1)","ACTIVE_COMPARATOR","Dosage Level(s): Low Dose",[13],"Drug: SKY-0515",{"label":15,"type":10,"description":16,"interventionNames":17},"Active Comparator (2)","Dosage Level(s): Mid Dose",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Active Comparator (3)","Dosage Level(s): High Dose",[13],{"label":23,"type":24,"description":25,"interventionNames":26},"Placebo Comparator (4)","PLACEBO_COMPARATOR","Matching placebo once daily oral",[27],"Drug: SKY-0515 Placebo",[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","SKY-0515","Type: Small molecule Dosage Level(s): Low, mid, high Route of Administration: Oral Dosage Frequency: Once daily Blinded Treatment Duration: 18 months Use: Experimental",[9,15,19],null,{"type":30,"name":36,"description":37,"armGroupLabels":38,"otherNames":34},"SKY-0515 Placebo","Route of Administration: Oral Dosage Frequency: Once daily Blinded Treatment Duration: 18 months Use: Experimental",[23],[40],{"name":41,"role":42,"phone":43,"phoneExt":34,"email":44},"Study Director, MD","CONTACT","6178580041","sky0515trials@skyhawktx.com",[46,62,75,87,97,115,133,149,168,184],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":34,"geoPoint":34,"contacts":54},"Buenos Aires British Hospital","RECRUITING","CABA","Buenos Aires","1280AEB","Argentina","AR",[55,59],{"name":56,"role":42,"phone":57,"phoneExt":34,"email":58},"Elizabeth Varela","+54 9 11 2309 1096","EVARELA@hbritanico.com.ar",{"name":60,"role":61,"phone":34,"phoneExt":34,"email":34},"Marcela Claudia Uribe Roca","PRINCIPAL_INVESTIGATOR",{"facility":63,"status":48,"city":49,"state":50,"zip":64,"country":52,"countryCode":53,"cosmosGeoPoint":34,"geoPoint":34,"contacts":65},"Instituto Argentino de Investigación Neurológica","C1015ABR",[66,69,73],{"name":67,"role":42,"phone":68,"phoneExt":34,"email":34},"Principal Investigator","+54 11 5429-3354",{"name":70,"role":42,"phone":71,"phoneExt":34,"email":72},"Karina Barroso","+54 9 11 6174-3158","karibarroso@yahoo.com.ar",{"name":74,"role":61,"phone":34,"phoneExt":34,"email":34},"Nelida Susana Garretto",{"facility":76,"status":48,"city":49,"state":50,"zip":77,"country":52,"countryCode":53,"cosmosGeoPoint":34,"geoPoint":34,"contacts":78},"CINME Centro de Investigaciones Metabólicas","C1056 AB",[79,81,85],{"name":67,"role":42,"phone":80,"phoneExt":34,"email":34},"+54 9 1150596124",{"name":82,"role":42,"phone":83,"phoneExt":34,"email":84},"Camila Di Nucci Traverso","+54 9 11 3668-7207","cdinuccitraverso@cinme.com.ar",{"name":86,"role":61,"phone":34,"phoneExt":34,"email":34},"Gabriela Beatriz Raina",{"facility":88,"status":48,"city":49,"state":50,"zip":89,"country":52,"countryCode":53,"cosmosGeoPoint":34,"geoPoint":34,"contacts":90},"Sanatorio Mater Dei","C1425",[91,95],{"name":92,"role":42,"phone":93,"phoneExt":34,"email":94},"Denise Pamela Paredes","+54 9 11 5663 6092","denisepamelaparedes@gmail.com",{"name":96,"role":61,"phone":34,"phoneExt":34,"email":34},"Emilia Gatto",{"facility":98,"status":48,"city":99,"state":100,"zip":101,"country":52,"countryCode":53,"cosmosGeoPoint":102,"geoPoint":107,"contacts":108},"Fundación Scherbovsky","Mendoza","Mendoza Province","M5500",{"type":103,"coordinates":104},"Point",[105,106],-68.84582,-32.88946,{"lat":106,"lon":105},[109,113],{"name":110,"role":42,"phone":111,"phoneExt":34,"email":112},"Mariangeles Samudio","+54 9 261 654-0777","m.samudio@fundacionscherbovsky.com",{"name":114,"role":61,"phone":34,"phoneExt":34,"email":34},"Sebastian Gustavo Rauek",{"facility":116,"status":48,"city":117,"state":117,"zip":118,"country":119,"countryCode":120,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"PSEG Centro de Pesquisa Clinica","São Paulo","04038002","Brazil","BR",{"type":103,"coordinates":122},[123,124],-46.63611,-23.5475,{"lat":124,"lon":123},[127,131],{"name":128,"role":42,"phone":129,"phoneExt":34,"email":130},"Heloisa Cruz","+55(11)98552-2485","heloisa.cruz@psegtrials.com",{"name":132,"role":61,"phone":34,"phoneExt":34,"email":34},"Paulo Victor Sgobbi de Souza",{"facility":134,"status":135,"city":136,"state":137,"zip":138,"country":139,"countryCode":140,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"North York General Hospital","NOT_YET_RECRUITING","Toronto","Ontario","M2K 1E1","Canada","CA",{"type":103,"coordinates":142},[143,144],-79.39864,43.70643,{"lat":144,"lon":143},[147],{"name":148,"role":61,"phone":34,"phoneExt":34,"email":34},"Rizek",{"facility":150,"status":48,"city":151,"state":152,"zip":153,"country":154,"countryCode":155,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"CETRAM (Centro de Trastornos del Movimiento)","Santiago","Santiago Metropolitan","9120500","Chile","CL",{"type":103,"coordinates":157},[158,159],-70.64827,-33.45694,{"lat":159,"lon":158},[162,166],{"name":163,"role":42,"phone":164,"phoneExt":34,"email":165},"Maria Consuelo Moos Migueles","+56 9 2278337","estudiosclinicos@cetram.cl",{"name":167,"role":61,"phone":34,"phoneExt":34,"email":34},"Pedro Chaná Cuevas",{"facility":169,"status":48,"city":170,"state":34,"zip":34,"country":171,"countryCode":172,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"Pineo Medical Ecosystem","Tbilisi","Georgia","GE",{"type":103,"coordinates":174},[175,176],44.83412,41.69143,{"lat":176,"lon":175},[179,183],{"name":180,"role":42,"phone":181,"phoneExt":34,"email":182},"Sophia Sopromadze, MD","+995 599 360 430","sophias@pineo.ge",{"name":180,"role":61,"phone":34,"phoneExt":34,"email":34},{"facility":185,"status":48,"city":170,"state":34,"zip":34,"country":171,"countryCode":172,"cosmosGeoPoint":186,"geoPoint":188,"contacts":189},"Simon Khechinashvili University Hospital",{"type":103,"coordinates":187},[175,176],{"lat":176,"lon":175},[190,194],{"name":191,"role":42,"phone":192,"phoneExt":34,"email":193},"Irine Khatiashvili, MD, Ph.D","+995577786578","irenekhat@yahoo.com",{"name":195,"role":61,"phone":34,"phoneExt":34,"email":34},"Irine Khatiashvili, MD, PhD",{"type":197,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100622055",false,"NCT07378644","Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease","A Phase 2\u002F3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease","FALCON-HD","Inclusion Criteria:\n\n* 25 years or older.\n* Huntington's Disease confirmed through genetic testing, with a specific change in exon 1 of the HTT gene (CAG repeat of 40 or more).\n* Total Functional Capacity (TFC) score of 10 or more).\n* Total Motor Score (TMS) of 6 or more).\n* Independence Score (IS) of 70 or more).\n* Women who can have children must have a negative pregnancy test before starting and use two types of birth control during the study and for 30 days after the last dose of the study drug.\n* Men must agree to use birth control during the study and for 90 days after the last dose.\n* Agree to sign a consent form and follow the study's rules and schedule.\n\nExclusion Criteria:\n\n* Other Serious health problems or brain\u002Fspinal issues that could interfere with the study or make procedures unsafe.\n* Conditions that interfere with protocol-specified assessments, like an implanted medical device or difficulty getting an MRI.\n* Cancer, except for some types of skin cancer, or a history of cancer in the last five years.\n* Severe allergies or have reacted badly to similar drugs in the past.\n* Taking medications or treatments that might interfere with the study.\n* Participated in another study or taken experimental drugs in the last two months (or longer for some drugs).\n* Any kind of gene therapy.\n* History of suicidal thoughts, severe depression, or have attempted suicide in the past year.\n* Liver function tests show significant abnormalities.\n* Positive for hepatitis B, hepatitis C, or HIV.\n* Pregnancy, breastfeeding, or planning to become pregnant during the study.","ALL","25 Years",{"count":208,"type":209},400,"ESTIMATED","INTERVENTIONAL",[212,213],"PHASE2","PHASE3","The goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD. This study includes men and women aged 25 and older who have HD confirmed by genetic testing and meet certain requirements for physical ability and independence.",[216],"Huntington Disease",[31,218,219,220,216,221,222,223],"Skyhawk","HTT","Neurodegenerative","mRNA","Splicing","Mutant Huntingtin protein","2026-06-30",{"date":226,"type":227},"2026-07-01","ACTUAL",{"date":229,"type":227},"2026-01-06",{"date":231,"type":209},"2029-08",{"name":5,"class":6},10]